

Safety Data Sheet according to (EC) No 1907/2006 as amended

Page 1 of 19

LOCTITE SF 7455 150ML

SDS No. : 153558 V003.0 Revision: 30.11.2023 printing date: 04.12.2023 Replaces version from: 10.06.2022

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier LOCTITE SF 7455 150ML

1.2. Relevant identified uses of the substance or mixture and uses advised against

Intended use: Primer, containing solvents

1.3. Details of the supplier of the safety data sheet

Henkel AG & Co. KGaA Henkelstr. 67 40589 Düsseldorf

Germany

Phone: +49 211 797 0

SDSinfo.Adhesive@henkel.com

For Safety Data Sheet updates please visit our website https://mysds.henkel.com/index.html#/appSelection or www.henkel-adhesives.com.

1.4. Emergency telephone number

The Henkel information service also provides an around-the-clock telephone service on phone no.+49-(0)211-797-3350 for exceptional cases.

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification (CLP):

| Flammable liquids | Category 2 |
|---|------------|
| H225 Highly flammable liquid and vapour. | |
| Skin irritation | Category 2 |
| H315 Causes skin irritation. | |
| Specific target organ toxicity - single exposure | Category 3 |
| H336 May cause drowsiness or dizziness. | |
| Target organ: Central nervous system | |
| Aspiration hazard | Category 1 |
| H304 May be fatal if swallowed and enters airways. | |
| Chronic hazards to the aquatic environment | Category 2 |
| H411 Toxic to aquatic life with long lasting effects. | |
| | |

2.2. Label elements

Label elements (CLP):

| Hazard pictogram: | |
|--|--|
| Contains | Hydrocarbons, C7, n-alkanes, isoalkanes, cyclics |
| Signal word: | Danger |
| Hazard statement: | H225 Highly flammable liquid and vapour. H304 May be fatal if swallowed and enters airways. H315 Causes skin irritation. H336 May cause drowsiness or dizziness. H411 Toxic to aquatic life with long lasting effects. |
| Supplemental information | Contains: N-tert-Butyl-2-benzothiazolesulfenamide May produce an allergic reaction. |
| Precautionary statement: Prevention | P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources.No smoking.P261 Avoid breathing vapors.P273 Avoid release to the environment. |
| Precautionary statement: Response | P302+P352 IF ON SKIN: Wash with plenty of soap and water. P331 Do NOT induce vomiting. P301+P310 IF SWALLOWED: Immediately call a POISON CENTER/doctor. |
| Precautionary statement: Storage | P403+P235 Store in a well-ventilated place. Keep cool. |

2.3. Other hazards

None if used properly.

Following substances are present in a concentration \geq the concentration limit for depiction in Section 3 and fulfill the criteria for PBT/vPvB, or were identified as endocrine disruptor (ED):

This mixture does not contain any substances in a concentration \geq the concentration limit for depiction in Section 3 that are assessed to be a PBT, vPvB or ED.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Declaration of the ingredients according to CLP (EC) No 1272/2008:

| Hazardous components CAS-No. EC Number REACH-Reg No. | Concentration | Classification | Specific Conc. Limits, M- factors and ATEs | Add. Information |
|--|---------------|---|---|---------------------|
| Hydrocarbons, C7, n-alkanes, isoalkanes, cyclics 64742-49-0 927-510-4 01-2119475515-33 | 50- 100 % | Aquatic Chronic 2, H411 Asp. Tox. 1, H304 Skin Irrit. 2, H315 Flam. Liq. 2, H225 STOT SE 3, H336 | inhalation:ATE = 23,31 mg/l;vapour | |
| cyclohexane 110-82-7 203-806-2 01-2119463273-41 | 5- < 10 % | Asp. Tox. 1, H304 STOT SE 3, H336 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 Flam. Liq. 2, H225 Skin Irrit. 2, H315 | M acute = 1 M chronic = 1 | EU OEL |
| n-Hexane 110-54-3 203-777-6 01-2119480412-44 | 0,1- < 1 % | Flam. Liq. 2, H225 Repr. 2, H361f Asp. Tox. 1, H304 STOT RE 2, H373 Skin Irrit. 2, H315 STOT SE 3, H336 Aquatic Chronic 2, H411 | STOT RE 2; H373; C >= 5 % | EU OEL |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 202-409-1 01-2119492625-29 | 0,1-< 1 % | Skin Sens. 1, H317 Aquatic Chronic 1, H410 Aquatic Acute 1, H400 | M acute = 10 M chronic = 1 | |

If no ATE values are displayed, please refer to LD/LC50 values in Section 11. For full text of the H - statements and other abbreviations see section 16 "Other information".

SECTION 4: First aid measures

4.1. Description of first aid measures

Inhalation:

Move to fresh air. If symptoms persist, seek medical advice.

Skin contact: Rinse with running water and soap. Obtain medical attention if irritation persists.

Eye contact: Rinse immediately with plenty of running water (for 10 minutes), seek medical attention from a specialist.

Ingestion:

Rinse mouth, drink 1-2 glasses of water, do not induce vomiting, consult a doctor. After ingestion or vomit: danger of product entering the lung.

4.2. Most important symptoms and effects, both acute and delayed

SKIN: Redness, inflammation.

Vapors may cause drowsiness and dizziness.

Prolonged or repeated contact may cause eye irritation.

ASPIRATION: Coughing, shortness of breath, nausea. Delayed effect: bronchopneumonia or pulmonary oedema

4.3. Indication of any immediate medical attention and special treatment needed

Small amounts of liquid aspirated into the respiratory system during ingestion or from vomiting may cause bronchopneumonia or pulmonary oedema.

Do not induce vomiting. Seek medical attention from a specialist.

SECTION 5: Firefighting measures

5.1. Extinguishing media Suitable extinguishing media:

water, carbon dioxide, foam, powder

Extinguishing media which must not be used for safety reasons: High pressure waterjet

5.2. Special hazards arising from the substance or mixture

In the event of a fire, carbon monoxide (CO), carbon dioxide (CO2) and nitrogen oxides (NOx) can be released.

5.3. Advice for firefighters

Wear self-contained breathing apparatus and full protective clothing, such as turn-out gear.

Additional information:

In case of fire, keep containers cool with water spray.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Ensure adequate ventilation. Avoid contact with skin and eyes. Wear protective equipment. Keep away from sources of ignition.

6.2. Environmental precautions

Do not empty into drains / surface water / ground water.

6.3. Methods and material for containment and cleaning up

For small spills wipe up with paper towel and place in container for disposal. For large spills absorb onto inert absorbent material and place in sealed container for disposal. Dispose of contaminated material as waste according to Section 13.

6.4. Reference to other sections

See advice in section 8

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Avoid skin and eye contact. See advice in section 8

Hygiene measures:

Wash hands before work breaks and after finishing work. Do not eat, drink or smoke while working. Good industrial hygiene practices should be observed.

7.2. Conditions for safe storage, including any incompatibilities

Ensure good ventilation/extraction.

Store in a cool, dry place.

Do not store near sources of heat or ignition, or reactive materials. Refer to Technical Data Sheet

7.3. Specific end use(s) Primer, containing solvents

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational Exposure Limits

Valid for

Germany

| Ingredient [Regulated substance] | ppm | mg/m ³ | Value type | Short term exposure limit category / Remarks | Regulatory list |
|--|-----|-------------------|--|--|-----------------|
| Cyclohexane 110-82-7 [CYCLOHEXANE] | 200 | 700 | Time Weighted Average (TWA): | Indicative | ECTLV |
| Cyclohexane 110-82-7 | 200 | 700 | Exposure limit(s): | 4 | TRGS 900 |
| Cyclohexane 110-82-7 | | | Short Term Exposure Classification: | Category II: substances with a resorptive effect. | TRGS 900 |
| n-Hexane 110-54-3 [N-HEXANE] | 20 | 72 | Time Weighted Average (TWA): | Indicative | ECTLV |
| n-Hexane 110-54-3 | 50 | 180 | Exposure limit(s): | 8 If the AGW and BGW values are complied with, there should be no risk of reproductive damage (see Number 2.7). | TRGS 900 |
| n-Hexane 110-54-3 | | | Short Term Exposure Classification: | Category II: substances with a resorptive effect. | TRGS 900 |

Predicted No-Effect Concentration (PNEC):

| Name on list | Environmental Compartment | Exposure period | | Remarks | | | |
|---|------------------------------------|--------------------|-----------------|---------|----------------|--------|----------------------------------|
| | | F | mg/l | ppm | mg/kg | others | |
| cyclohexane 110-82-7 | aqua (freshwater) | | 0,207 mg/l | | | | |
| cyclohexane 110-82-7 | aqua (marine water) | | 0,207 mg/l | | | | |
| cyclohexane 110-82-7 | aqua (intermittent releases) | | 0,207 mg/l | | | | |
| cyclohexane 110-82-7 | sediment (freshwater) | | | | 16,68 mg/kg | | |
| cyclohexane 110-82-7 | sediment (marine water) | | | | 16,68 mg/kg | | |
| cyclohexane 110-82-7 | Soil | | | | 3,38 mg/kg | | |
| cyclohexane 110-82-7 | sewage treatment plant (STP) | | 3,24 mg/l | | | | |
| cyclohexane 110-82-7 | Air | | | | | | |
| cyclohexane 110-82-7 | Predator | | | | | | no potential for bioaccumulation |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | aqua (freshwater) | | 0,0023 mg/l | | | | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | Freshwater - intermittent | | 0,00071 mg/l | | | | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | aqua (marine water) | | 0,00023 mg/l | | | | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | sewage treatment plant (STP) | | 100 mg/l | | | | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | sediment (freshwater) | | | | 0,08 mg/kg | | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | sediment (marine water) | | | | 0,008 mg/kg | | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | Soil | | | | 0,796 mg/kg | | |

Derived No-Effect Level (DNEL):

| Hydocarbos, C7, a-alkanes, isoalkanes, G712-49-0 Workers inhalatota Long term systemic effects 200 mg/kg Hydocarbos, C7, a-alkanes, isoalkanes, G712-69-0 Workers inhalatota Long term systemic effects 2085 mg/m3 Hydocarbos, C7, a-alkanes, isoalkanes, cycles General oppalation dermal copusition apog term systemic effects 417 mg/m3 Hydocarbos, C7, a-alkanes, isoalkanes, cycles General oppalation dermal copusition apog term systemic effects 417 mg/m3 Hydocarbos, C7, a-alkanes, isoalkanes, cycles General oppalation inhalation Leng term systemic effects 417 mg/m3 Hydocarbos, C7, a-alkanes, isoalkanes, cycles General oppalation inhalation Accurs/soft term exposure - systemic effects 149 mg/kg Hydocarbos, C7, a-alkanes, isoalkanes, cycles Workers inhalation Accurs/soft term exposure - systemic effects 700 mg/m3 no potential for bisoaccumulation Hydocarbos, C7, a-alkanes, isoalkanes, cyclebexane Workers inhalation Accurs/soft term exposure - local 700 mg/m3 no potential for bisoaccumulation Hydocarbos, C7, a-alkanes, isoalkanes, cyclebexane Workers inhalation Accurs/soft term exposure - local | Name on list | Application Area | Route of Exposure | Health Effect | Exposure Time | Value | Remarks |
|--|---|---------------------|----------------------|--------------------------------|------------------|--------------|------------------|
| 6472-4-0-0 | | Workers | dermal | | | 300 mg/kg | |
| Hydrocarbons. (7, n-alkanes, isoalkanes, cyclics Workers inhalation Long term cysparser- systemic effects 2085 mg/m3 6472.4-20-0 Hydrocarbons. (7, n-alkanes, isoalkanes, cyclics General population dermal cyclics 14.9 mg/kg 6472.4-20-0 General population General population inhalation Long term cycourser 14.9 mg/kg Hydrocarbons. (7, n-alkanes, isoalkanes, cyclics General population inhalation Long term cycourser 14.9 mg/kg Corport cyclics General population inhalation Long term cyclics 14.9 mg/kg Cyclics General population inhalation Long term cyclics 10.9 potential for 110-82-7 Workers inhalation Acuesbort term cyclobecane 700 mg/m3 no potential for 110-82-7 Workers inhalation Long term cyclobecane 700 mg/m3 no potential for 110-82-7 Workers inhalation Long term cyclobecane 2016 mg/m3 no potential for 110-82-7 Workers inhalation Long term cyclobecane 2016 mg/m3 no potential for 110-82-7 | | | | | | | |
| dord 2-0-0.0 (c) 142-0-0.0 (c) 142-0.0 (c) 142-0.0 | | Workers | inhalation | | | 2085 mg/m3 | |
| Hydocurbons, C., n. alkanes, isoalkanes, cycles General nopulation Long term exposure - systemic effects 149 mg/kg Hydocurbons, C., n. alkanes, isoalkanes, cycles General nopulation Long term exposure - systemic effects 149 mg/kg Hydocurbons, C., n. alkanes, isoalkanes, cycles General nopulation Long term exposure - systemic effects 149 mg/kg Hydocurbons, C., n. alkanes, isoalkanes, cycles General nopulation Long term exposure - systemic effects 149 mg/kg Hydocurbons, C., n. alkanes, isoalkanes, cycles General nopulation Long term exposure - systemic effects 149 mg/kg Hydocurbons, C., n. alkanes, isoalkanes, cyclebersane Workers inhalation Long term exposure - systemic effects 700 mg/m3 no potential for bioaccumulation Ho32-7 Workers inhalation Long term exposure - systemic effects 700 mg/m3 no potential for bioaccumulation cyclohesane General population Long term exposure - systemic effects 2016 mg/kg no potential for bioaccumulation 110-82-7 General population Long term exposure - systemic effects 2016 mg/kg no potential for bioaccumulation 110-82-7 General population Inhalation exposu | 5 | | | | | | |
| cyclics of AF22-49-0 (General population exposure - systemic effects 447 mg/m3 exposure - systemic effects 4 | | General | dermal | | | 149 mg/kg | |
| Hydnocations, C7, n=ilkanes, isoalkanes, cyclics General population Inhalation Long term exposure - systemic effects 447 mg/m3 Hydnocations, C7, n=ilkanes, isoalkanes, cyclobexane General population oral Long term 149 mg/kg cyclobexane Workers inhalation Long term 149 mg/kg cyclobexane Workers inhalation Acute/short term 700 mg/m3 no potential for bioaccumulation 110-32.7 Workers inhalation Acute/short term 700 mg/m3 no potential for bioaccumulation 110-32.7 Workers inhalation Long term 700 mg/m3 no potential for bioaccumulation 110-32.7 Workers inhalation Long term 700 mg/m3 no potential for bioaccumulation 110-32.7 Workers inhalation Long term 2016 mg/m3 no potential for bioaccumulation 110-32.7 General inhalation Long term 412 mg/m3 no potential for bioaccumulation 110-32.7 population inhalation Acute/short term 412 mg/m3 no potentiial for bioaccumulation | cyclics | | | exposure - | | | |
| cyclespopulationexposure - systemic effects149Hydeocarbons, C7, n-ukkmes, isoalkanes, cyclesGeneral populationrond exposure - systemic effects149G724-29-0cyclesinhalatio exposure - cyclessare700 mg/m3no potential for bioaccumulation110-82-7Workersinhalatio attabationActuckshort term exposure - local700 mg/m3no potential for bioaccumulation110-82-7Workersinhalation attabationActuckshort term exposure - local700 mg/m3no potential for bioaccumulationcyclohesaneWorkersinhalation attabationLong term exposure - local effects700 mg/m3no potential for bioaccumulation110-82-7Workersinhalation attabationLong term exposure - local effects700 mg/m3no potential for bioaccumulation110-82-7Workersdermal ethosare - systemic effects700 mg/m3no potential for bioaccumulation110-82-7General populationLong term exposure - systemic effects2016 mg/m3no potential for bioaccumulation110-82-7General populationinhalationAcuts/bort term exposure - systemic effects412 mg/m3no potential for bioaccumulation110-82-7genpalationinhalation exposure - systemic effects412 mg/m3no potential for bioaccumulation110-82-7genpalationinhalation exposure - systemic effects110-82-7no potential for bioaccumulation110-82-7 | | Conoral | inholation | | | 117 mg/m2 | |
| G472-0-0 '' systemic effects uncertain of the population concerns 149 mg/kg cyclobexame gopulation Long term 149 mg/kg no polential for cyclobexame Workers inhalation Acute/short term 700 mg/m3 no polential for cyclobexame Workers inhalation Acute/short term 700 mg/m3 no polential for cyclobexame Workers inhalation Acute/short term 700 mg/m3 no polential for cyclobexame Workers inhalation Long term 700 mg/m3 no polential for cyclobexame Workers inhalation Long term 700 mg/m3 no polential for tioAs2-7 Workers inhalation Lang term 2016 mg/m3 no polential for tioAs2-7 population workers inhalation Acute/short term 2016 mg/m3 no polential for tioAs2-7 population error Acute/short term 2016 mg/m3 no polential for tioAs2-7 population error systemic effects </td <td></td> <td></td> <td>minaration</td> <td>U</td> <td></td> <td>447 mg/m5</td> <td></td> | | | minaration | U | | 447 mg/m5 | |
| cyclicks cyclohckune 110-82-7populationexpseume effectsProvide systemic effectsProvide systemic effectscyclohckune clockune 110-82-7Workersinhalatio inhalatioAcute/short term exposure - local700 mg/m3 bioaccumulationno potential for bioaccumulationcyclohckane cyclohckane tlo-82-7Workersinhalatio inhalatioLong term exposure - local700 mg/m3 cyclohckaneno potential for bioaccumulationcyclohckane tlo-82-7Workersinhalatio tlo-82-7Long term exposure - local700 mg/m3 cyclohckaneno potential for bioaccumulationcyclohckane cyclohckaneWorkersinhalation exposure - local elfects700 mg/m3 cyclohckaneno potential for bioaccumulationli0-82-7Workersinhalation exposure - local elfects2016 mg/m2 cyclohckaneno potential for bioaccumulationli0-82-7populationinhalation exposure - local elfects2016 mg/m2 cyclohckaneno potential for bioaccumulationli0-82-7populationinhalation exposure - local elfects412 mg/m3 bioaccumulationno potential for bioaccumulationli0-82-7populationorenal ensposure - local elfects412 mg/m3 bioaccumulationno potential for bioaccumulationli0-82-7populationorenal exposure - local elfectsLong term exposure - local412 mg/m3 bioaccumulationli0-82-7general populationorenal exposure - local elfects1186 mg/m3 bioaccumulati | 64742-49-0 | | | systemic effects | | | |
| 64742-9-0 inhalation systemic effects no potential for bioaccumulation 110-82-7 Workers inhalation Acute/short term exposure - local effects 700 mg/m3 no potential for bioaccumulation 110-82-7 Workers inhalation Acute/short term exposure - systemic effects 700 mg/m3 no potential for bioaccumulation cyclohexane Workers inhalation Long term exposure - systemic effects 700 mg/m3 no potential for bioaccumulation cyclohexane Workers inhalation Long term exposure - systemic effects 700 mg/m3 no potential for bioaccumulation cyclohexane Workers inhalation Long term exposure - systemic effects 700 mg/m3 no potential for bioaccumulation cyclohexane General inhalation Long term exposure - systemic effects 2016 mg/kg no potential for bioaccumulation cyclohexane General inhalation Acute/short term exposure - systemic effects 412 mg/m3 no potential for bioaccumulation cyclohexane General inhalation Acute/short term exposure - systemic effects 412 mg/m3 no potential for bioaccumulation cyclohexane General inhalation forg term exposure - systemic effects 412 mg/m3 no potential for bioaccumulation cyclohexane G | | | oral | | | 149 mg/kg | |
| cyclohexane 110-82-7Workersinhalation expourse- systemic effects700 mg/m3 populationno potential for bioaccumulation110-82-7Workersinhalation attack-short term expourse- systemic effects700 mg/m3 populationno potential for bioaccumulation110-82-7Workersinhalation attack-short term exposure- systemic effects700 mg/m3 populationno potential for bioaccumulation110-82-7Workersinhalation attack-short term exposure- systemic effects700 mg/m3 populationno potential for bioaccumulation110-82-7Workersinhalation attack-short term exposure- systemic effects700 mg/m3 populationno potential for bioaccumulation110-82-7Workersdermal populationLong term exposure- systemic effects2016 mg/kg populationno potential for bioaccumulation110-82-7General populationinhalation exposure- systemic effects412 mg/m3 populationno potential for bioaccumulationcyclohexane 110-82-7General populationcore term exposure- systemic effects412 mg/m3 populationno potential for bioaccumulationcyclohexane 110-82-7General populationcore term exposure- systemic effects412 mg/m3 populationno potential for bioaccumulationcyclohexane 110-82-7General populationcore term exposure- systemic effects206 mg/m3 populationno potential for bioaccumulationcyclohexane 110-82-7General popula | 2 | population | | | | | |
| cyclobexane 110-82-7Workersinhalation inhalationAcute/short term exposure - systemic effects700 mg/m3 no potential for hioaccumulationcyclobexane 110-82-7Workersinhalation inhalationLong term exposure - systemic effects700 mg/m3 no potential for hioaccumulationcyclobexane 110-82-7Workersinhalation exposure - systemic effects700 mg/m3 no potential for hioaccumulationcyclobexane 110-82-7Workersinhalation exposure - systemic effects2016 mg/kg no potential for hioaccumulationcyclobexane 110-82-7General populationinhalation exposure - systemic effects2016 mg/kg no potential for hioaccumulationcyclobexane 110-82-7General populationinhalation exposure - systemic effects412 mg/m3 no potential for hioaccumulationcyclobexane 110-82-7General populationinhalation exposure - systemic effects412 mg/m3 no potential for hioaccumulationcyclobexane 110-82-7General populationLong term exposure - systemic effects118 mg/kg no potential for hioaccumulationcyclobexane 110-82-7General populationLong term exposure - systemic effects206 mg/m3 no potential for hioaccumulationcyclobexane 110-82-7General populationLong term exposure - systemic effects206 mg/m3 no potential for hioaccumulationcyclobexane 110-82-7General populationLong term exposure - systemic effects206 mg/m3 no potential for | | Workers | inhalation | Acute/short term | | 700 mg/m3 | |
| cyclohexane 110.82-7Workersinhalation response re- systemic effects700 mg/m3no potential for bioaccumulation10.82-7WorkersinhalationLong term exposure - systemic effects700 mg/m3no potential for bioaccumulation10.82-7WorkersinhalationLong term exposure - systemic effects700 mg/m3no potential for bioaccumulationcyclohexane cyclohexaneWorkersdermalLong term exposure - systemic effects2016 mg/m3no potential for bioaccumulationcyclohexane cyclohexaneGeneral populationinhalation active fiftets412 mg/m3no potential for bioaccumulationcyclohexane cyclohexaneGeneral populationinhalation active fiftets412 mg/m3no potential for bioaccumulationcyclohexane cyclohexaneGeneral populationinhalation active fiftets412 mg/m3no potential for bioaccumulationcyclohexane cyclohexaneGeneral populationinhalation active fiftets1186 mg/kgno potential for bioaccumulationcyclohexane cyclohexaneGeneral populationoral and Long term exposure - systemic effects206 mg/m3no potential for bioaccumulationtilo-82-7population populationinhalation and cyclohexane1186 mg/m3no potential for bioaccumulationtilo-82-7population populationinhalation and cyclohexane1186 mg/m3no potential for bioaccumulationtilo-82-7general population | 110-82-7 | | | | | | bioaccumulation |
| 110-82-7 exposure - systemic effects 700 mg/m3 bioaccumulation cvclohexane revolution Workers inhalation Long term exposure - systemic effects 700 mg/m3 no potential for bioaccumulation cvclohexane rulo-82-7 Workers dermal Long term exposure - systemic effects 700 mg/m3 no potential for bioaccumulation cvclohexane rulo-82-7 Workers dermal Log term exposure - systemic effects 2016 mg/kg no potential for bioaccumulation cvclohexane rulo-82-7 General population inhalation inhalation Actuc/short term exposure - systemic effects 412 mg/m3 no potential for bioaccumulation cvclohexane rulo-82-7 General population inhalation exposure - local effects 1186 mg/kg no potential for bioaccumulation 110-82-7 general population dermal Long term exposure - local effects 1186 mg/kg no potential for bioaccumulation rulo-82-7 general population oral Long term exposure - local exposure - local 1186 mg/kg no potential for bioaccumulation rulo-82-7 general population inhalation exposure - local 206 mg/m3 no potential for bioaccumulation rulo-82-7 general population inhalation exposure - local 206 mg/m3 no potential for bioaccumulation rulo-82-7 general pop | cvclohexane | Workers | inhalation | | | 700 mg/m3 | no potential for |
| cyclohexane 110-82-7Workersinhalation inhalationLong term systemic effects700 mg/m3no potential for bioaccumulationcyclohexane 110-82-7WorkersinhalationLong term exposure - local exposure - systemic effects2016 mg/kgno potential for bioaccumulationcyclohexane 110-82-7Workersdermal inhalationLong term exposure - systemic effects2016 mg/kgno potential for bioaccumulationcyclohexane cyclohexane cyclohexaneGeneral populationinhalationAcute/short term exposure - systemic effects412 mg/m3no potential for bioaccumulationcyclohexane cyclohexaneGeneral populationinhalationAcute/short term exposure - systemic effects412 mg/m3no potential for bioaccumulationcyclohexane cyclohexaneGeneral populationoral exposure - systemic effects1186 mg/kgno potential for bioaccumulationcyclohexane t10-82-7General populationoral exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane t10-82-7General populationoral exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane t10-82-7General populationlong term exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane t10-82-7General populationoral exposure - systemic effects206 mg/m3no potential for bioaccumulationt10-82-7General p | | | | exposure - | | 6 - | |
| 110-82-7 exposure - systemic effects - bioaccumulation cyclohexane 110-82-7 Workers inhalation effects Long term exposure - local effects 700 mg/m3 no potential for bioaccumulation 110-82-7 Workers dermal inhalation Long term exposure - systemic effects 2016 mg/kg no potential for bioaccumulation cyclohexane 110-82-7 General population inhalation Acute/short term exposure - systemic effects 412 mg/m3 no potential for bioaccumulation cyclohexane 110-82-7 General population inhalation Acute/short term exposure - systemic effects 412 mg/m3 no potential for bioaccumulation cyclohexane 110-82-7 General population dermal population Cong term exposure - systemic effects 1186 mg/kg no potential for bioaccumulation cyclohexane 110-82-7 General population oral Long term exposure - systemic effects 206 mg/m3 no potential for bioaccumulation cyclohexane 110-82-7 General population inhalation Long term exposure - systemic effects 206 mg/m3 no potential for bioaccumulation rectohxane 110-82-7 General population inhalation Long term exposure - systemic effects 206 mg/m3 no potential for bioaccumu | avalahavana | Worker | inhol-4: | | <u> </u> | $700 ma/m^2$ | no notontial f |
| exclusionystemic effects | | workers | innalation | | | /00 mg/m3 | |
| 110-82-7 exposure - local exposure - local ioiaccumulation eyclohexane 110-82-7 Workers dermal Long term exposure - systemic effects 2016 mg/kg no potential for bioaccumulation cyclohexane 110-82-7 General population inhalation Acute/short term exposure - systemic effects 412 mg/m3 no potential for bioaccumulation cyclohexane 110-82-7 General population inhalation Acute/short term exposure - systemic effects 412 mg/m3 no potential for bioaccumulation cyclohexane 110-82-7 General population dermal erfects Long term exposure - systemic effects 1186 mg/kg no potential for bioaccumulation cyclohexane cyclohexane cyclohexane General population oral Long term exposure - systemic effects 59,4 mg/kg no potential for bioaccumulation cyclohexane cyclohexane General population inhalation Long term exposure - systemic effects 206 mg/m3 no potential for bioaccumulation cyclohexane 110-82-7 General population inhalation Long term exposure - systemic effects 206 mg/m3 no potential for bioaccumulation no-star General population inhalation Long term exposure - systemic effects 16 mg/m3 in optential | | | | | | | |
| eyclohexane cyclohexane 110-82-7Workersdermal dermal exposure - systemic effects2016 mg/kg no potential for bioaccumulationcyclohexane cyclohexane cyclohexaneGeneral populationinhalation actur/systemic effects412 mg/m3 ho potential for bioaccumulationcyclohexane cyclohexane cyclohexaneGeneral populationinhalation exposure - exystemic effects412 mg/m3 ho potential for bioaccumulationcyclohexane cyclohexaneGeneral populationinhalation exposure - local effects1186 mg/kg ho potential for bioaccumulationcyclohexane cyclohexaneGeneral populationoral cong term exposure - systemic effects1186 mg/kg ho potential for bioaccumulationcyclohexane cyclohexaneGeneral populationoral exposure - systemic effects59.4 mg/kg ho potential for bioaccumulationcyclohexane cyclohexane cyclohexaneGeneral populationinhalation exposure - systemic effects206 mg/m3 ho potential for bioaccumulation110-82-7General populationinhalation exposure - systemic effects206 mg/m3 ho potential for bioaccumulation110-82-7General populationinhalation exposure - local effects206 mg/m3 ho potential for bioaccumulation110-82-7General populationinhalation exposure - systemic effects16 mg/m3 ho potential for bioaccumulationno botential for bioaccumulationinhalation exposure - systemic effects10 mg/m3 ho potential for bioaccumu | | Workers | inhalation | | | 700 mg/m3 | |
| eyclohexane 110-82-7Workersdermal erm exposure - systemic effects2016 mg/kgno potential for bioaccumulation110-82-7General populationinhalationAcute/short term exposure - systemic effects412 mg/m3no potential for bioaccumulation110-82-7General populationinhalationAcute/short term exposure - local412 mg/m3no potential for bioaccumulationcyclohexane t10-82-7General populationdermal effectsLong term exposure - local1186 mg/kgno potential for bioaccumulationcyclohexane t10-82-7General populationdermal exposure - systemic effects1186 mg/kgno potential for bioaccumulationcyclohexane t10-82-7General populationoral exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane t10-82-7General populationinhalation exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane t10-82-7General populationinhalation exposure - systemic effects206 mg/m3no potential for bioaccumulationt10-82-7gopulationinhalation exposure - systemic effectsLong term exposure - systemic effects206 mg/m3no potential for bioaccumulationt10-82-7gopulationinhalation exposure - systemic effectsLong term exposure - systemic effects206 mg/m3no potential for bioaccumulationt10-82-7gopulationinhalation exposure - system | 110-82-7 | | | | | | bioaccumulation |
| cyclohexane cyclohexane 110-82-7General populationinhalation inhalationAcute/short term exposure - systemic effects412 mg/m3 bioaccumulationcyclohexane cyclohexane 110-82-7General populationinhalationAcute/short term exposure - systemic effects412 mg/m3 bioaccumulationcyclohexane cyclohexane cyclohexane cyclohexane cyclohexane cyclohexaneGeneral populationInhalation412 mg/m3 cystemic effectsno potential for bioaccumulationcyclohexane cyclohexane cyclohexane cyclohexaneGeneral populationdermal exposure - systemic effects1186 mg/kg bioaccumulationno potential for bioaccumulationcyclohexane cyclohexane 110-82-7General populationoral exposure - systemic effects206 mg/m3 no potential for bioaccumulationcyclohexane t10-82-7General populationInhalation exposure - systemic effects206 mg/m3 mo potential for bioaccumulationcyclohexane t10-82-7General populationInhalation exposure - systemic effects206 mg/m3 mo potential for bioaccumulationcyclohexane t10-82-7General populationInhalation exposure - systemic effects10 mg/m3 mo potential for bioaccumulationt10-82-7General populationInhalation exposure - systemic effects10 mg/m3 mo potential for bioaccumulationt10-82-7General populationInhalation exposure - systemic effects10 mg/m3 mo potential for bioaccumulationt10-82-7G | cyclohexane | Workers | dermal | | | 2016 mg/kg | no potential for |
| cyclohexane 110-82-7General populationinhalation inhalationAcute/short term exposure - systemic effects412 mg/m3no potential for bioaccumulation110-82-7General populationinhalationAcute/short term exposure - local effects412 mg/m3no potential for bioaccumulation110-82-7General populationdermal exposure - local effects1186 mg/kgno potential for bioaccumulation110-82-7General populationoral populationLong term exposure - systemic effects59.4 mg/kgno potential for bioaccumulation110-82-7General populationoral populationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulation110-82-7General populationinhalation exposure - systemic effects206 mg/m3no potential for bioaccumulation110-82-7General populationinhalation exposure - systemic effects206 mg/m3no potential for bioaccumulation110-82-7General populationLong term exposure - systemic effects11 mg/m3no potential for bioaccumulation< | 110-82-7 | | | | | | bioaccumulation |
| 110-82-7 population exposure - systemic effects bioaccumulation cyclohexane General population inhalation Acute/short term exposure - local effects 412 mg/m3 no potential for bioaccumulation cyclohexane General population dermal Long term exposure - local effects 1186 mg/kg no potential for bioaccumulation cyclohexane General population oral Long term exposure - systemic effects 59,4 mg/kg no potential for bioaccumulation cyclohexane General population oral Long term exposure - systemic effects 59,4 mg/kg no potential for bioaccumulation cyclohexane General population inhalation Long term exposure - systemic effects 206 mg/m3 no potential for bioaccumulation cyclohexane General population inhalation Long term exposure - systemic effects 206 mg/m3 no potential for bioaccumulation ni-Hexane General population inhalation Long term exposure - systemic effects 206 mg/m3 no potential for bioaccumulation n-Hexane General population inhalation Long term exposure - systemic effects 16 mg/m3 10 mg/m3 10 mg/m3 10 mg/m3 10 mg/m3 10 mg | cyclohevane | General | inhalation | | | 412 mg/m3 | no potential for |
| cyclohexane 110-82-7General populationinhalation actuc/short term exposure - local412 mg/m3no potential for bioaccumulationcyclohexane 110-82-7General populationdermal cyclohexaneLong term exposure - systemic effects1186 mg/kgno potential for bioaccumulationcyclohexane 110-82-7General populationoral cyclohexaneLong term exposure - systemic effects59,4 mg/kgno potential for bioaccumulation110-82-7General populationinhalation exposure - systemic effectsLong term exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane 110-82-7General populationinhalation inhalationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulationn-Hexane 110-54-3General populationinhalation exposure - systemic effects10 mg/m3no potential for bioaccumulationn-Hexane 110-54-3General populationinhalation exposure - systemic effects10 mg/m3no potential for bioaccumulationn-Hexane 110-54-3General populationinhalation exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects4 mg/kg | 2 | | minaration | | | 412 mg/m3 | |
| 110-82-7populationexposure - local effectsbioaccumulationcyclohexane 110-82-7General populationdermal exposure - systemic effects1186 mg/kgno potential for bioaccumulationcyclohexane 110-82-7General populationoral exposure - systemic effectsDog term exposure - systemic effects59,4 mg/kgno potential for bioaccumulationcyclohexane cyclohexane 110-82-7General populationinhalation exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane 110-82-7General populationinhalation exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane 110-82-7General populationinhalation exposure - systemic effects206 mg/m3no potential for bioaccumulation110-82-7General populationinhalation exposure - systemic effects206 mg/m3no potential for bioaccumulation110-54-3General populationLong term exposure - systemic effects11 mg/m3n-Hexane 110-54-3General populationdermal exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationdermal exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8Workersinhalation inhalationLong term exposure - systemic effectsN-tert-But | | | | | | | |
| cyclohexane cyclohexane 110-82-7General populationdermal dermal populationLong term exposure - systemic effects1186 mg/kg ho potential for bioaccumulation10-82-7General populationoral oralLong term exposure - systemic effects1186 mg/kgno potential for bioaccumulation10-82-7General populationoral oralLong term exposure - systemic effects59.4 mg/kgno potential for bioaccumulation10-82-7General populationinhalationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulation10-82-7General populationinhalationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulation10-82-7General populationinhalationLong term exposure - systemic effects10 mg/m3no potential for bioaccumulation110-82-7General populationinhalationLong term exposure - systemic effects10 mg/m3no potential for bioaccumulationn-Hexane 110-54-3General populationinhalation exposure - systemic effects11 mg/kgno populationn-Hexane 110-54-3General populationdermal exposure - systemic effects11 mg/kg11 mg/kgn-Hexane 110-54-3General populationdermal exposure - systemic effects11 mg/kg11 mg/kgn-Hexane 110-54-3General populationoral exposure - systemic effects11 mg/kg11 mg/kg | | | inhalation | | | 412 mg/m3 | |
| 110-82-7populationexposure - systemic effectsbioaccumulationcyclohexane 110-82-7General populationoralLong term exposure - systemic effects59,4 mg/kgno potential for bioaccumulationcyclohexane 110-82-7General populationinhalation populationcong term exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane 110-82-7General populationinhalation populationcong term exposure - systemic effects206 mg/m3no potential for bioaccumulationn-Hexane 110-54-3General populationinhalation effectscong term exposure - systemic effects16 mg/m3n-Hexane 110-54-3General populationdermal exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationdermal exposure - systemic effects5.3 mg/kgn-Hexane 110-54-3General populationdermal exposure - systemic effects5.3 mg/kgn-Hexane 110-54-3General populationcong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects4 mg/kgn-Hexane 110-54-3General populationoral exposure - systemic effects14 mg/m3n-Hexane 110-54-3Workersinhalation exposure - systemic effects14 mg/m3 | 110-02-7 | population | | | | | bloaccumulation |
| cyclohexane cyclohexane 110-82-7General populationoral coral populationLong term exposure - systemic effects59,4 mg/kgno potential for bioaccumulation10-82-7General populationinhalationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulation10-82-7General populationinhalationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulation110-82-7General populationinhalationLong term exposure - local effects206 mg/m3no potential for bioaccumulation110-82-7General populationinhalationLong term exposure - systemic effects16 mg/m3no bioaccumulation110-54-3General populationdermal exposure - systemic effectsLong term exposure - systemic effects11 mg/kg110-54-3Workersdermal populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects14 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects14 mg/m3 | | | dermal | | | 1186 mg/kg | |
| cyclohexane 110-82-7General populationoral oralLong term exposure - systemic effects59,4 mg/kgno potential for bioaccumulationcyclohexane 110-82-7General populationinhalation populationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane 110-82-7General populationinhalation populationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulationr.Hexane 110-54-3General populationinhalation exposure - local effects206 mg/m3no potential for bioaccumulationn-Hexane 110-54-3General populationinhalation exposure - systemic effects16 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationdermal exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationdermal exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationcorg term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects14 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects14 mg/m3n-Hexane 110-54-3Workersinhalation exposure - systemic effects14 mg/m3 | 110-82-7 | population | | | | | bioaccumulation |
| 110-82-7populationexposure - systemic effects206 mg/m3no potential for bioaccumulation10-82-7general populationinhalationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulation10-82-7general populationinhalationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulation110-82-7general populationinhalationLong term exposure - local effects206 mg/m3no potential for bioaccumulation110-84-3General populationinhalationLong term exposure - systemic effects16 mg/m3110-54-3Workersdermal exposure - systemic effects11 mg/kg110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects4 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects14 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects14 mg/m3n-Hexane 110-54-3General populationLong term e | cyclohexane | General | oral | | | 59,4 mg/kg | no potential for |
| cyclohexane 110-82-7General populationinhalation imalationLong term exposure - systemic effects206 mg/m3no potential for bioaccumulationcyclohexane 110-82-7General populationinhalation imalationLong term exposure - local effects206 mg/m3no potential for bioaccumulationn-Hexane 110-54-3General populationinhalation imalationLong term exposure - systemic effects16 mg/m3n-Hexane 110-54-3General populationinhalation exposure - systemic effects16 mg/m3n-Hexane 110-54-3Workersdermal exposure - systemic effects11 mg/kg110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects14 mg/m3n-Hexane 110-54-3Workersinhalation exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8Workersinhalation inhalationLong term exposure - systemic effects14 mg/m3 | 110-82-7 | population | | exposure - | | | bioaccumulation |
| 110-82-7populationexposure - systemic effectsbioaccumulationcyclohexane 110-82-7General populationinhalationLong term exposure - local effects206 mg/m3no potential for bioaccumulationn-Hexane 110-54-3General populationinhalationLong term exposure - systemic effects16 mg/m3n-Hexane 110-54-3Workersdermal exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects14 mg/m3n-Hexane 110-54-3Workersinhalation exposure - systemic effects14 mg/m3 | avalahayana | Conoral | inholation | | | 206 mg/m2 | no notantial for |
| cyclohexane cyclohexane 110-82-7General populationinhalation inhalationsystemic effects206 mg/m3no potential for bioaccumulationn-Hexane 110-54-3General populationinhalation populationLong term exposure - systemic effects16 mg/m310 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3Workersinhalation populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3Workersinhalation populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects206 mg/m314 mg/m3n-Hexane 110-54-3Workersinhalation exposure - systemic effects14 mg/m3n-Hexane 110-54-3Workersinhalation exposure - systemic effects14 mg/m3 | 2 | | minaration | | | 200 mg/m3 | |
| 110-82-7populationexposure - local effectsbioaccumulationn-Hexane 110-54-3General populationLong term exposure - systemic effects16 mg/m3n-Hexane 110-54-3Workersdermal ermalLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3Workersinhalation exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3Workersinhalation exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects14 mg/m3n-Hexane 110-54-3Workersinhalation exposure - systemic effects14 mg/m3 | | 1 1 | | systemic effects | | | |
| n-Hexane 110-54-3General populationinhalation inhalationLong term exposure - systemic effects16 mg/m3n-Hexane 110-54-3WorkersdermalLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationdermalLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationdermalLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationLong term exposure - systemic effects4 mg/kgn-Hexane 110-54-3Workersinhalation exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide S1-8Workersinhalation inhalationLong term exposure - systemic effects14 mg/m3 | | | inhalation | | | 206 mg/m3 | |
| 110-54-3populationexposure - systemic effectsn-Hexane 110-54-3WorkersdermalLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoral exposure - systemic effects4 mg/kgn-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects4 mg/kgn-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide SoleWorkersinhalationAcute/short term14 mg/m3 | 110-82-7 | population | | | | | bioaccumulation |
| n-Hexane 110-54-3WorkersdermalLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationdermalLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3General populationdermalLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoralLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoralLong term exposure - systemic effects14 mg/m3n-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide 05-31-8WorkersinhalationAcute/short term14 mg/m3 | | | inhalation | | | 16 mg/m3 | |
| n-Hexane 110-54-3WorkersdermalLong term exposure - systemic effects11 mg/kgn-Hexane 110-54-3General populationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoralLong term exposure - systemic effects4 mg/kgN-tert-Butylbenzothiazole-2-sulphenamide 95-31-8WorkersinhalationLong term exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamideWorkersinhalationAcute/short term14 mg/m3 | 110-54-3 | population | | | | | |
| 110-54-3exposure - systemic effectsn-Hexane 110-54-3General populationdermalLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoralLong term exposure - systemic effects75 mg/m3N-Hexane 110-54-3General populationoralLong term exposure - systemic effects4 mg/kgN-tert-Butylbenzothiazole-2-sulphenamide 95-31-8WorkersinhalationLong term exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide WorkersWorkersinhalationAcute/short term14 mg/m3 | n-Hexane | Workers | dermal | | | 11 mg/kg | |
| n-Hexane 110-54-3General populationdermalLong term exposure - systemic effects5,3 mg/kgn-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoralLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoralLong term exposure - systemic effects4 mg/kgN-tert-Butylbenzothiazole-2-sulphenamide N-tert-Butylbenzothiazole-2-sulphenamideWorkersinhalationLong term exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide N-tert-Butylbenzothiazole-2-sulphenamideWorkersinhalationAcute/short term14 mg/m3 | | | - | exposure - | | 00 | |
| 110-54-3populationexposure - systemic effectsn-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoralLong term exposure - systemic effects4 mg/kgN-tert-Butylbenzothiazole-2-sulphenamide 95-31-8WorkersinhalationLong term exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide VorkersWorkersinhalationAcute/short term14 mg/m3 | n Havana | Cananal | dower-1 | | <u> </u> | 5.2 mg/lsc | |
| n-Hexane 110-54-3WorkersinhalationLong term exposure - systemic effects75 mg/m3n-Hexane 110-54-3General populationoralLong term exposure - systemic effects4 mg/kgn-Hexane 110-54-3General populationoralLong term exposure - systemic effects4 mg/kgN-tert-Butylbenzothiazole-2-sulphenamide 95-31-8WorkersinhalationLong term exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide WorkersWorkersinhalationAcute/short term14 mg/m3 | | | uermal | | | 5,5 mg/kg | |
| 110-54-3exposure - systemic effectsn-Hexane 110-54-3General populationoralLong term exposure - systemic effects4 mg/kgN-tert-Butylbenzothiazole-2-sulphenamide 95-31-8WorkersinhalationLong term exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide WorkersWorkersinhalationAcute/short term14 mg/m3 | | | | systemic effects | | | |
| n-Hexane 110-54-3General populationoralLong term exposure - systemic effects4 mg/kgN-tert-Butylbenzothiazole-2-sulphenamide 95-31-8WorkersinhalationLong term exposure - systemic effects14 mg/m3N-tert-Butylbenzothiazole-2-sulphenamide WorkersWorkersinhalationLong term exposure - systemic effects14 mg/m3 | | Workers | inhalation | | | 75 mg/m3 | |
| n-Hexane General oral Long term 4 mg/kg 110-54-3 population oral Long term 4 mg/kg N-tert-Butylbenzothiazole-2-sulphenamide Workers inhalation Long term 14 mg/m3 95-31-8 N-tert-Butylbenzothiazole-2-sulphenamide Workers inhalation Acute/short term 14 mg/m3 | 110-34-3 | | 1 | | | | |
| N-tert-Butylbenzothiazole-2-sulphenamide Workers inhalation Long term exposure - systemic effects 14 mg/m3 N-tert-Butylbenzothiazole-2-sulphenamide Workers inhalation Acute/short term 14 mg/m3 | | | oral | Long term | 1 | 4 mg/kg | |
| N-tert-Butylbenzothiazole-2-sulphenamide Workers inhalation Long term exposure - systemic effects 14 mg/m3 N-tert-Butylbenzothiazole-2-sulphenamide Workers inhalation Acute/short term 14 mg/m3 | 110-54-3 | population | | | | | |
| 95-31-8 exposure - systemic effects N-tert-Butylbenzothiazole-2-sulphenamide Workers inhalation Acute/short term 14 mg/m3 | N-tert-Butylbenzothiazole-2-sulphenamide | Workers | inhalation | | | 14 mg/m3 | |
| N-tert-Butylbenzothiazole-2-sulphenamide Workers inhalation Acute/short term 14 mg/m3 | v 1 | | | exposure - | | | |
| | N test Detaile see this 1. 2. 1.1. | W/l | lut at at | | | 14 | |
| 195-31-8 lexposure - | N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | workers | innalation | Acute/short term exposure - | | 14 mg/m3 | |

LOCTITE SF 7455 150ML

SDS No.: 153558 V003.0

| I | 1 | | systemic effects | | |
|---|--------------------|------------|--|-----------|--|
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | Workers | inhalation | Long term exposure - local effects | 14 mg/m3 | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | Workers | inhalation | Acute/short term exposure - local effects | 14 mg/m3 | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | Workers | dermal | Long term exposure - systemic effects | 67 mg/kg | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | Workers | dermal | Acute/short term exposure - systemic effects | 534 mg/kg | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | General population | inhalation | Long term exposure - systemic effects | 3,5 mg/m3 | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | General population | inhalation | Acute/short term exposure - systemic effects | 3,5 mg/m3 | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | General population | inhalation | Long term exposure - local effects | 3,5 mg/m3 | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | General population | inhalation | Acute/short term exposure - local effects | 3,5 mg/m3 | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | General population | dermal | Long term exposure - systemic effects | 33 mg/kg | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | General population | dermal | Acute/short term exposure - systemic effects | 266 mg/kg | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | General population | oral | Long term exposure - systemic effects | 1 mg/kg | |
| N-tert-Butylbenzothiazole-2-sulphenamide 95-31-8 | General population | oral | Acute/short term exposure - systemic effects | 8 mg/kg | |

Biological Exposure Indices:

| Ingredient [Regulated substance] | Parameters | Biological specimen | Sampling time | Conc. | Basis of biol. exposure index | Remark | Additional Information |
|----------------------------------|---|------------------------|---|----------|----------------------------------|--------|---------------------------|
| Cyclohexane 110-82-7 | 1,2- Cyclohexane diol, with hydrolysis | Creatinine in urine | Sampling time period is for long-term exposures, at the end of the shift after several preceding ones./ Sampling time period is at end of exposure or at end of shift. | 150 mg/g | DE BGW | | |
| n-Hexane 110-54-3 | Hexane-2,5- dione plus 4,5- Dihydroxy-2- hexanone | Urine | Sampling time: End of shift. | 5 mg/l | DE BAT | | |
| n-Hexane 110-54-3 | Hexane-2,5- dione plus 4,5- Dihydroxy-2- hexanone (with hydrolysis) | Urine | Sampling time: End of shift. | 5 mg/l | DE BGW | | |

8.2. Exposure controls:

Engineering controls: Ensure good ventilation/extraction. An approved mask or respirator fitted with an organic vapour cartridge should be worn if the product is used in a poorly ventilated area Filter type: A (EN 14387)

The type. A (ER 1450

Hand protection:

Chemical-resistant protective gloves (EN 374).

Suitable materials for short-term contact or splashes (recommended: at least protection index 2, corresponding to > 30 minutes permeation time as per EN 374):

nitrile rubber (NBR; >= 0.4 mm thickness)

Suitable materials for longer, direct contact (recommended: protection index 6, corresponding to > 480 minutes permeation time as per EN 374):

nitrile rubber (NBR; >= 0.4 mm thickness)

This information is based on literature references and on information provided by glove manufacturers, or is derived by analogy with similar substances. Please note that in practice the working life of chemical-resistant protective gloves may be considerably shorter than the permeation time determined in accordance with EN 374 as a result of the many influencing factors (e.g. temperature). If signs of wear and tear are noticed then the gloves should be replaced.

Eye protection:

Safety glasses with sideshields or chemical safety goggles should be worn if there is a risk of splashing. Protective eye equipment should conform to EN166.

Skin protection: Wear suitable protective clothing. Protective clothing should conform to EN 14605 for liquid splashes or to EN 13982 for dusts.

Advices to personal protection equipment:

The information provided on personal protective equipment is for guidance purposes only. A full risk assessment should be conducted prior to using this product to determine the appropriate personal protective equipment to suit local conditions. Personal protective equipment should conform to the relevant EN standard.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

| Delivery form | liquid |
|--|--|
| Colour | colourless, Clear |
| Odor | Aliphatic |
| Physical state | liquid |
| Melting point | Not applicable, Product is a liquid |
| Solidification temperature | -75 °C (-103 °F) |
| Initial boiling point | 96 - 98 °C (204.8 - 208.4 °F) |
| Flammability | Flammable liquid |
| Explosive limits | I I I |
| lower | 1.1 %(V); |
| upper | 6,7 %(V); |
| 11 | Upper/lower explosion limit |
| Flash point | -4 °C (24.8 °F); Tagliabue closed cup |
| Auto-ignition temperature | 223 °C (433.4 °F) |
| Decomposition temperature | Not applicable, Substance/mixture is not self-reactive, no organic |
| | peroxide and does not decompose under foreseen conditions of use |
| pH | Not applicable, Product is non-soluble (in water). |
| Viscosity (kinematic) | 0.6 mm2/s |
| (20 °C (68 °F);) | •,• |
| Viscosity (kinematic) | <= 20,5 mm2/s |
| (40 °C (104 °F);) | , |
| Solubility (qualitative) | Not miscible |
| (20 °C (68 °F); Solvent: Water) | |
| Partition coefficient: n-octanol/water | Not applicable |
| | Mixture |
| Vapour pressure | 5,33 kPa |
| (20 °C (68 °F)) | |
| Density | 0,68 g/cm3 None |
| | |
| | |

(20 °C (68 °F)) Relative vapour density: (20 °C) Particle characteristics

9.2. Other information

Other information not applicable for this product

SECTION 10: Stability and reactivity

10.1. Reactivity

Reacts with strong oxidants. Acids. Reducing agents. Strong bases.

10.2. Chemical stability

Stable under recommended storage conditions.

10.3. Possibility of hazardous reactions

See section reactivity

10.4. Conditions to avoid

Stable under normal conditions of storage and use.

10.5. Incompatible materials

See section reactivity.

10.6. Hazardous decomposition products

carbon oxides. Hydrocarbons nitrogen oxides Rapid polymerisation may generate excessive heat and pressure.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute oral toxicity:

The mixture is classified based on calculation method referring to the classified substances present in the mixture.

| Hazardous substances CAS-No. | Value type | Value | Species | Method |
|---|---------------|---------------|---------|---|
| Hydrocarbons, C7, n- alkanes, isoalkanes, cyclics 64742-49-0 | LD50 | > 5.840 mg/kg | rat | not specified |
| cyclohexane 110-82-7 | LD50 | > 5.000 mg/kg | rat | equivalent or similar to OECD Guideline 401 (Acute Oral Toxicity) |
| n-Hexane 110-54-3 | LD50 | 16.000 mg/kg | rat | OECD Guideline 401 (Acute Oral Toxicity) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | LD50 | 6.850 mg/kg | rat | not specified |

3,4

Not applicable Product is a liquid

Acute dermal toxicity:

The mixture is classified based on calculation method referring to the classified substances present in the mixture.

| Hazardous substances | Value | Value | Species | Method |
|--------------------------|-------|---------------|---------|--|
| CAS-No. | type | | | |
| Hydrocarbons, C7, n- | LD50 | > 2.800 mg/kg | rat | other guideline: |
| alkanes, isoalkanes, | | | | _ |
| cyclics | | | | |
| 64742-49-0 | | | | |
| cyclohexane | LD50 | > 2.000 mg/kg | rabbit | equivalent or similar to OECD Guideline 402 (Acute |
| 110-82-7 | | | | Dermal Toxicity) |
| n-Hexane | LD50 | > 2.000 mg/kg | rabbit | not specified |
| 110-54-3 | | | | - |
| N-tert-Butyl-2- | LD50 | > 7.940 mg/kg | rabbit | not specified |
| benzothiazolesulfenamide | | | | • |
| 95-31-8 | | | | |

Acute inhalative toxicity:

The mixture is classified based on calculation method referring to the classified substances present in the mixture.

| Hazardous substances CAS-No. | Value type | Value | Test atmosphere | Exposure time | Species | Method |
|---|--|---------------|-----------------|------------------|---------|---|
| Hydrocarbons, C7, n- alkanes, isoalkanes, cyclics 64742-49-0 | LC50 | > 23,3 mg/l | vapour | 4 h | rat | equivalent or similar to OECD Guideline 403 (Acute Inhalation Toxicity) |
| Hydrocarbons, C7, n- alkanes, isoalkanes, cyclics 64742-49-0 | Acute toxicity estimate (ATE) | 23,31 mg/l | vapour | | | Expert judgement |
| cyclohexane 110-82-7 | LC50 | > 32,880 mg/l | vapour | 4 h | rat | equivalent or similar to OECD Guideline 403 (Acute Inhalation Toxicity) |
| n-Hexane 110-54-3 | LC50 | > 31,86 mg/l | vapour | 4 h | rat | not specified |

Skin corrosion/irritation:

The mixture is classified based on calculation method referring to the classified substances present in the mixture.

| Hazardous substances CAS-No. | Result | Exposure time | Species | Method |
|---|----------------|------------------|---------|--|
| Hydrocarbons, C7, n- alkanes, isoalkanes, cyclics 64742-49-0 | irritating | 4 h | rabbit | equivalent or similar to OECD Guideline 404 (Acute Dermal Irritation / Corrosion) |
| cyclohexane 110-82-7 | irritating | | rabbit | Weight of evidence |
| n-Hexane 110-54-3 | not irritating | | rabbit | OECD Guideline 404 (Acute Dermal Irritation / Corrosion) |

Serious eye damage/irritation:

The mixture is classified based on calculation method referring to the classified substances present in the mixture.

| Hazardous substances | Result | Exposure | Species | Method |
|----------------------|----------------|----------|---------|--|
| CAS-No. | | time | | |
| Hydrocarbons, C7, n- | not irritating | | rabbit | FDA Guideline |
| alkanes, isoalkanes, | _ | | | |
| cyclics | | | | |
| 64742-49-0 | | | | |
| cyclohexane | slightly | | rabbit | equivalent or similar to OECD Guideline 405 (Acute Eye |
| 110-82-7 | irritating | | | Irritation / Corrosion) |
| n-Hexane | not irritating | | rabbit | not specified |
| 110-54-3 | | | | - |

Respiratory or skin sensitization:

The mixture is classified based on threshold limits referring to the classified substances present in the mixture.

| Hazardous substances CAS-No. | Result | Test type | Species | Method |
|---|-----------------|---------------------------------------|------------|---|
| Hydrocarbons, C7, n- alkanes, isoalkanes, cyclics 64742-49-0 | not sensitising | Guinea pig maximisation test | guinea pig | OECD Guideline 406 (Skin Sensitisation) |
| cyclohexane 110-82-7 | not sensitising | Buehler test | guinea pig | equivalent or similar to OECD Guideline 406 (Skin Sensitisation) |
| n-Hexane 110-54-3 | not sensitising | Mouse local lymphnode assay (LLNA) | mouse | OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) |

Germ cell mutagenicity:

The mixture is classified based on threshold limits referring to the classified substances present in the mixture.

| Hazardous substances CAS-No. | Result | Type of study / Route of administration | Metabolic activation / Exposure time | Species | Method |
|--|-----------|--|--|---------|---|
| cyclohexane 110-82-7 | negative | bacterial reverse mutation assay (e.g Ames test) | with and without | | equivalent or similar to OECD Guideline 471 (Bacterial Reverse Mutation Assay) |
| cyclohexane 110-82-7 | negative | mammalian cell gene mutation assay | with and without | | equivalent or similar to OECD Guideline 476 (In vitro Mammalian Cell Gene Mutation Test) |
| n-Hexane 110-54-3 | negative | bacterial reverse mutation assay (e.g Ames test) | with and without | | OECD Guideline 471 (Bacterial Reverse Mutation Assay) |
| n-Hexane 110-54-3 | negative | mammalian cell gene mutation assay | with and without | | OECD Guideline 476 (In vitro Mammalian Cell Gene Mutation Test) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | negative | bacterial reverse mutation assay (e.g Ames test) | with and without | | OECD Guideline 471 (Bacterial Reverse Mutation Assay) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | ambiguous | in vitro mammalian chromosome aberration test | with and without | | OECD Guideline 473 (In vitro Mammalian Chromosome Aberration Test) |
| cyclohexane 110-82-7 | negative | inhalation: vapour | | rat | equivalent or similar to OECD Guideline 475 (Mammalian Bone Marrow Chromosome Aberration Test) |
| n-Hexane 110-54-3 | negative | inhalation: vapour | | mouse | not specified |
| n-Hexane 110-54-3 | negative | inhalation: vapour | | rat | not specified |

Carcinogenicity

The mixture is classified based on threshold limits referring to the classified substances present in the mixture.

| Hazardous components CAS-No. | Result | Route of application | Exposure time / Frequency of treatment | Species | Sex | Method |
|---------------------------------|------------------|-----------------------|---|---------|--------|--|
| n-Hexane 110-54-3 | not carcinogenic | inhalation: vapour | 2 y 6 h/d; 5 d/w | mouse | female | OECD Guideline 451 (Carcinogenicity Studies) |

Reproductive toxicity:

The mixture is classified based on threshold limits referring to the classified substances present in the mixture.

| Hazardous substances CAS-No. | Result / Value | Test type | Route of application | Species | Method |
|---------------------------------|--|-----------------------------|-----------------------|---------|--|
| cyclohexane 110-82-7 | NOAEL F1 7000 ppm | two- generation study | inhalation: vapour | rat | equivalent or similar to OECD Guideline 416 (Two- Generation Reproduction Toxicity Study) |
| n-Hexane 110-54-3 | NOAEL P 9000 ppm NOAEL F1 3000 ppm NOAEL F2 3000 ppm | Two generation study | inhalation: vapour | rat | OECD Guideline 416 (Two- Generation Reproduction Toxicity Study) |

STOT-single exposure:

The mixture is classified based on threshold limits referring to the classified substances present in the mixture.

| Hazardous substances CAS-No. | Assessment | Route of exposure | Target Organs | Remarks |
|---------------------------------|-----------------------------------|-------------------|---------------|---------|
| cyclohexane 110-82-7 | Category 3 with narcotic effects. | | | |

STOT-repeated exposure:

The mixture is classified based on threshold limits referring to the classified substances present in the mixture.

| Hazardous substances CAS-No. | Result / Value | Route of application | Exposure time / Frequency of treatment | Species | Method |
|--|--------------------|-----------------------|--|---------|---|
| cyclohexane 110-82-7 | | inhalation: vapour | 13-14 w 6 h/d, 5 d/w | mouse | EPA OPPTS 870.3465 (90-Day Inhalation Toxicity) |
| n-Hexane 110-54-3 | NOAEL 568 mg/kg | oral: gavage | 90 d 5 d/w | rat | not specified |
| n-Hexane 110-54-3 | NOAEL 500 ppm | inhalation: vapour | 90 d 6 h/d; 5 d/w | mouse | OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | LOAEL >= 200 mg/kg | oral: gavage | daily | rat | not specified |

Aspiration hazard:

The mixture is classified based on Viscosity data.

| Hazardous substances CAS-No. | Viscosity (kinematic) Value | Temperature | Method | Remarks |
|---------------------------------|--------------------------------|-------------|---------------|---------|
| cyclohexane 110-82-7 | 0,41 mm2/s | 40 °C | not specified | |
| n-Hexane 110-54-3 | 0,45 mm2/s | 25 °C | not specified | |

11.2 Information on other hazards

not applicable

SECTION 12: Ecological information

General ecological information:

Do not empty into drains / surface water / ground water.

12.1. Toxicity

Toxicity (Fish):

The mixture is classified based on calculation method referring to the classified substances present in the mixture.

The table below presents the data of the classified substances present in the mixture.

| Hazardous substances | Value | Value | Exposure time | Species | Method |
|---|-------|---------------|---------------|---------|--|
| CAS-No. | type | | | | |
| Hydrocarbons, C7, n-alkanes, isoalkanes, cyclics 64742-49-0 | LL50 | 8,2 mg/l | 96 h | | EPA-660 (Methods for Acute Toxicity Tests with Fish, Macroinvertebrates and Amphibians) |
| cyclohexane 110-82-7 | LC50 | 4,53 mg/l | 96 h | 1 1 | OECD Guideline 203 (Fish, Acute Toxicity Test) |
| n-Hexane 110-54-3 | LC50 | > 1 - 10 mg/l | 96 h | 1 | OECD Guideline 203 (Fish, Acute Toxicity Test) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | LC50 | 1,38 mg/l | 96 h | 5 1 | OECD Guideline 203 (Fish, Acute Toxicity Test) |

Toxicity (aquatic invertebrates):

The mixture is classified based on calculation method referring to the classified substances present in the mixture.

The table below presents the data of the classified substances present in the mixture.

| Hazardous substances CAS-No. | Value type | Value | Exposure time | Species | Method |
|---|---------------|----------|---------------|---------------|--|
| Hydrocarbons, C7, n-alkanes, isoalkanes, cyclics 64742-49-0 | EL50 | 4,5 mg/l | 48 h | Daphnia magna | OECD Guideline 202 (Daphnia sp. Acute Immobilisation Test) |
| cyclohexane 110-82-7 | EC50 | 0,9 mg/l | 48 h | Daphnia magna | OECD Guideline 202 (Daphnia sp. Acute Immobilisation Test) |
| n-Hexane 110-54-3 | EC50 | 2,1 mg/l | 48 h | Daphnia magna | OECD Guideline 202 (Daphnia sp. Acute Immobilisation Test) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | EC50 | 1,3 mg/l | 48 h | Daphnia magna | OECD Guideline 202 (Daphnia sp. Acute Immobilisation Test) |

Chronic toxicity (aquatic invertebrates):

The table below presents the data of the classified substances present in the mixture.

| Hazardous substances | Value | Value | Exposure time | Species | Method |
|---|-------|-----------|---------------|---------|--|
| CAS-No. | type | | | | |
| Hydrocarbons, C7, n-alkanes, isoalkanes, cyclics 64742-49-0 | NOELR | 2,6 mg/l | 21 d | 1 0 | OECD 211 (Daphnia magna, Reproduction Test) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | NOEC | 0,08 mg/l | 21 d | 1 0 | OECD 211 (Daphnia magna, Reproduction Test) |

Toxicity (Algae):

The mixture is classified based on calculation method referring to the classified substances present in the mixture.

The table below presents the data of the classified substances present in the mixture.

| Hazardous substances | Value | Value | Exposure time | Species | Method |
|---|-------|---------------|---------------|---|--|
| CAS-No. | type | | | | |
| Hydrocarbons, C7, n-alkanes, isoalkanes, cyclics 64742-49-0 | EL50 | 3,1 mg/l | 72 h | Pseudokirchneriella subcapitata | OECD Guideline 201 (Alga, Growth Inhibition Test) |
| Hydrocarbons, C7, n-alkanes, isoalkanes, cyclics 64742-49-0 | NOELR | 0,5 mg/l | 72 h | Pseudokirchneriella subcapitata | OECD Guideline 201 (Alga, Growth Inhibition Test) |
| cyclohexane 110-82-7 | EC50 | 9,317 mg/l | 72 h | Selenastrum capricornutum (new name: Pseudokirchneriella subcapitata) | OECD Guideline 201 (Alga, Growth Inhibition Test) |
| cyclohexane 110-82-7 | NOEC | 0,95 mg/l | 72 h | Selenastrum capricornutum (new name: Pseudokirchneriella subcapitata) | OECD Guideline 201 (Alga, Growth Inhibition Test) |
| n-Hexane 110-54-3 | EC50 | > 1 - 10 mg/l | 72 h | not specified | OECD Guideline 201 (Alga, Growth Inhibition Test) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | EC50 | 0,071 mg/l | 72 h | Scenedesmus capricornutum | OECD Guideline 201 (Alga, Growth Inhibition Test) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | NOEC | 0,023 mg/l | 72 h | Scenedesmus capricornutum | OECD Guideline 201 (Alga, Growth Inhibition Test) |

Toxicity (microorganisms):

The mixture is classified based on calculation method referring to the classified substances present in the mixture.

The table below presents the data of the classified substances present in the mixture.

| Hazardous substances | Value | Value | Exposure time | Species | Method |
|-------------------------|-------|---------------|---------------|---------------|--|
| CAS-No. | type | | | | |
| cyclohexane 110-82-7 | IC50 | 29 mg/l | 15 h | other: | not specified |
| n-Hexane 110-54-3 | EC50 | > 1 - 10 mg/l | 3 h | not specified | OECD Guideline 209 (Activated Sludge, Respiration Inhibition Test) |

12.2. Persistence and degradability

The table below presents the data of the classified substances present in the mixture.

| Hazardous substances CAS-No. | Result | Test type | Degradability | Exposure time | Method |
|---|----------------------------|-----------|---------------|------------------|---|
| Hydrocarbons, C7, n-alkanes, isoalkanes, cyclics 64742-49-0 | readily biodegradable | aerobic | 77,05 % | 28 d | OECD Guideline 301 F (Ready Biodegradability: Manometric Respirometry Test) |
| cyclohexane 110-82-7 | readily biodegradable | aerobic | 77 % | 28 d | OECD Guideline 301 F (Ready Biodegradability: Manometric Respirometry Test) |
| n-Hexane 110-54-3 | readily biodegradable | aerobic | 81 % | 28 d | OECD Guideline 301 F (Ready Biodegradability: Manometric Respirometry Test) |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | not readily biodegradable. | aerobic | 0 % | 28 d | OECD Guideline 301 C (Ready Biodegradability: Modified MITI Test (I)) |

12.3. Bioaccumulative potential

The table below presents the data of the classified substances present in the mixture.

| Hazardous substances CAS-No. | Bioconcentratio n factor (BCF) | Exposure time | Temperature | Species | Method |
|---------------------------------|-----------------------------------|---------------|-------------|------------------------|--|
| cyclohexane 110-82-7 | 167 | | | Pimephales promelas | QSAR (Quantitative Structure Activity Relationship) |

12.4. Mobility in soil

The table below presents the data of the classified substances present in the mixture.

| Hazardous substances CAS-No. | LogPow | Temperature | Method |
|---|--------|-------------|---|
| Hydrocarbons, C7, n-alkanes, isoalkanes, cyclics 64742-49-0 | 4,66 | | EU Method A.8 (Partition Coefficient) |
| cyclohexane 110-82-7 | 3,44 | 25 °C | QSAR (Quantitative Structure Activity Relationship) |
| n-Hexane 110-54-3 | 4 | 20 °C | other guideline: |
| N-tert-Butyl-2- benzothiazolesulfenamide 95-31-8 | 3,36 | 25 °C | OECD Guideline 117 (Partition Coefficient (n-octanol / water), HPLC Method) |

12.5. Results of PBT and vPvB assessment

The table below presents the data of the classified substances present in the mixture.

| Hazardous substances | PBT / vPvB |
|--|--|
| CAS-No. | |
| Hydrocarbons, C7, n-alkanes, isoalkanes, | Not fulfilling Persistent, Bioaccumulative and Toxic (PBT), very Persistent and very |
| cyclics | Bioaccumulative (vPvB) criteria. |
| 64742-49-0 | |
| cyclohexane | Not fulfilling Persistent, Bioaccumulative and Toxic (PBT), very Persistent and very |
| 110-82-7 | Bioaccumulative (vPvB) criteria. |
| n-Hexane | Not fulfilling Persistent, Bioaccumulative and Toxic (PBT), very Persistent and very |
| 110-54-3 | Bioaccumulative (vPvB) criteria. |
| N-tert-Butyl-2-benzothiazolesulfenamide | Not fulfilling Persistent, Bioaccumulative and Toxic (PBT), very Persistent and very |
| 95-31-8 | Bioaccumulative (vPvB) criteria. |

12.6. Endocrine disrupting properties

not applicable

12.7. Other adverse effects

No data available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Product disposal:

Do not empty into drains / surface water / ground water. Dispose of in accordance with local and national regulations.

Disposal of uncleaned packages:

After use, tubes, cartons and bottles containing residual product should be disposed of as chemically contaminated waste in an authorised legal land fill site or incinerated.

Waste code

08 04 09* waste adhesives and sealants containing organic solvents and other dangerous substances

The valid EWC waste code numbers are source-related. The manufacturer is therefore unable to specify EWC waste codes for the articles or products used in the various sectors. The EWC codes listed are intended as a recommendation for users. We will be happy to advise you.

SECTION 14: Transport information

| 14.1. | UN number or] | ID number | | |
|-------|------------------------------|---|--|--|
| | ADR | 1206 | | |
| | RID | 1206 | | |
| | ADN | 1206 | | |
| | IMDG | 1206 | | |
| | IATA | 1206 | | |
| 14.2. | UN proper shipping name | | | |
| | ADR | HEPTANES (solution) | | |
| | RID | HEPTANES (solution) | | |
| | ADN | HEPTANES (solution) | | |
| | IMDG | HEPTANES (solution) | | |
| | IATA | Heptanes (solution) | | |
| 14.3. | Transport hazard class(es) | | | |
| | ADR | 3 | | |
| | RID | 3 | | |
| | ADN | 3 | | |
| | IMDG | 3 | | |
| | IATA | 3 | | |
| 14.4. | Packing group | | | |
| | ADR | II | | |
| | RID | II | | |
| | ADN | II | | |
| | IMDG | II | | |
| | IATA | Π | | |
| 14.5. | Environmental | hazards | | |
| | | | | |
| | ADR | Environmentally Hazardous | | |
| | RID | Environmentally Hazardous | | |
| | ADN | Environmentally Hazardous | | |
| | IMDG | Marine Pollutant | | |
| | IATA | not applicable | | |
| 14.6. | Special precautions for user | | | |
| | ADR | not applicable Tunnelcode: (D/E) | | |
| | RID | not applicable | | |
| | ADN | not applicable | | |
| | IMDG | not applicable | | |
| | IATA | not applicable | | |
| 14.7. | Maritime trans | port in bulk according to IMO instruments | | |
| | not applicable | | | |

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixtureOzone Depleting Substance (ODS) (Regulation (EC) No 1005/2009):Not applicablePrior Informed Consent (PIC) (Regulation (EU) No 649/2012):Not applicablePersistent organic pollutants (Regulation (EU) 2019/1021):Not applicable

VOC content (2010/75/EC) 100 %

3

15.2. Chemical safety assessment

A chemical safety assessment has not been carried out.

National regulations/information (Germany):

WGK:

WGK 2: significantly water endangering (Ordinance on facilities for handling substances that are hazardous to water (AwSV)) Classification according to AwSV, Annex 1 (5.2)

Storage class according to TRGS 510:

SECTION 16: Other information

The labelling of the product is indicated in Section 2. The full text of all abbreviations indicated by codes in this safety data sheet are as follows: H225 Highly flammable liquid and vapour. H304 May be fatal if swallowed and enters airways. H315 Causes skin irritation. H317 May cause an allergic skin reaction. H336 May cause drowsiness or dizziness. H361f Suspected of damaging fertility. H373 May cause damage to organs through prolonged or repeated exposure. H400 Very toxic to aquatic life. H410 Very toxic to aquatic life with long lasting effects. H411 Toxic to aquatic life with long lasting effects. ED: Substance identified as having endocrine disrupting properties EU OEL: Substance with a Union workplace exposure limit EU EXPLD 1: Substance listed in Annex I, Reg (EC) No. 2019/1148 EU EXPLD 2 Substance listed in Annex II, Reg (EC) No. 2019/1148 Substance of very high concern (REACH Candidate List) SVHC: PBT: Substance fulfilling persistent, bioaccumulative and toxic criteria PBT/vPvB: Substance fulfilling persistent, bioaccumulative and toxic plus very persistent and very bioaccumulative criteria

vPvB:

Further information:

This Safety Data Sheet has been produced for sales from Henkel to parties purchasing from Henkel, is based on Regulation (EC) No 1907/2006 and provides information in accordance with applicable regulations of the European Union only. In that respect, no statement, warranty or representation of any kind is given as to compliance with any statutory laws or regulations of any other jurisdiction or territory other than the European Union. When exporting to territories other than the European Union, please consult with the respective Safety Data Sheet of the concerned territory to ensure compliance or liaise with Henkel's Product Safety and Regulatory Affairs Department (SDSinfo.Adhesive@henkel.com) prior to export to other territories than the European Union.

Substance fulfilling very persistent and very bioaccumulative criteria

This information is based on our current level of knowledge and relates to the product in the state in which it is delivered. It is intended to describe our products from the point of view of safety requirements and is not intended to guarantee any particular properties.

Dear Customer,

Henkel is committed to creating a sustainable future by promoting opportunities along the entire value chain. If you would like to contribute by switching from a paper to the electronic version of SDS, please contact the local Customer Service representative. We recommend to use a non-personal email address (e.g. SDS@your_company.com).

Relevant changes in this safety data sheet are indicated by vertical lines at the left margin in the body of this document. Corresponding text is displayed in a different color on shadowed fields.

SDS No.: 153558 V003.0